The stock of Coherus Biosciences Inc (CHRS) has seen a -2.69% decrease in the past week, with a 8.25% gain in the past month, and a -18.48% decrease in the past quarter. The volatility ratio for the week is 7.78%, and the volatility levels for the past 30 days are at 8.63% for CHRS. The simple moving average for the past 20 days is -11.64% for CHRS’s stock, with a -21.09% simple moving average for the past 200 days.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
Additionally, the 36-month beta value for CHRS is 0.98. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CHRS is 111.29M and currently, short sellers hold a 29.26% ratio of that float. The average trading volume of CHRS on May 13, 2025 was 1.79M shares.
CHRS) stock’s latest price update
Coherus Biosciences Inc (NASDAQ: CHRS) has experienced a decline in its stock price by -11.28 compared to its previous closing price of 1.02. However, the company has seen a fall of -2.69% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-12 that Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers – Head, Investor Relations Denny Lanfear – Chief Executive Officer Theresa LaVallee – Chief Scientific & Development Officer Rosh Dias – Chief Medical Officer Sameer Goregaoker – Executive Vice President, Commercial Bryan McMichael – Chief Financial Officer Conference Call Participants Kripa Devarakonda – Truist Securities Brian Cheng – JPMorgan Mike Nedelcovych – TD Cowen Colleen Kusy – Baird Douglas Tsao – H.C. Wainwright Operator Good day and thank you for standing by.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -5.21% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.76% of loss for the given period.
Volatility was left at 8.63%, however, over the last 30 days, the volatility rate increased by 7.78%, as shares sank -8.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.29% lower at present.
During the last 5 trading sessions, CHRS fell by -4.60%, which changed the moving average for the period of 200-days by -43.85% in comparison to the 20-day moving average, which settled at $1.0232. In addition, Coherus Biosciences Inc saw -34.43% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.58 for the present operating margin
- 0.53 for the gross margin
The net margin for Coherus Biosciences Inc stands at -0.66. The total capital return value is set at -0.99.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 4.83 points at debt to capital in total, while cash flow to debt ratio is standing at 0.0. The debt to equity ratio resting at -1.26. The interest coverage ratio of the stock is -8.25.
Currently, EBITDA for the company is 60.94 million with net debt to EBITDA at -1.49. When we switch over and look at the enterprise to sales, we see a ratio of 1.28. The receivables turnover for the company is 3.27for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.00.
Conclusion
In conclusion, Coherus Biosciences Inc (CHRS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
